Who Owns Lantheus Medical Imaging Company?

Lantheus Medical Imaging Bundle

Get Full Bundle:

	BCG	$15	$10
	5 FORCES	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Lantheus Medical Imaging?

Understanding a company's ownership is crucial for grasping its strategic direction and accountability. Lantheus Holdings, Inc., now a public entity, has a history shaped by significant ownership transitions.

From its inception as New England Nuclear Corporation in 1956 to its re-launch as Lantheus Medical Imaging in 2008 under Avista Capital Partners, the company's journey has been marked by evolving ownership structures.

Lantheus Holdings, Inc., a radiopharmaceutical leader based in North Billerica, Massachusetts, reported worldwide revenue of $1.53 billion and free cash flow of $493.1 million for the full year 2024. As of December 31, 2024, the company held $912.8 million in cash and cash equivalents, reflecting its strong financial position. The company's commitment to innovation is evident in its product offerings, including advancements in diagnostic and therapeutic products for cardiology, oncology, and neurology, such as those analyzed in the Lantheus Medical Imaging BCG Matrix.

The company that is now known as Lantheus Medical Imaging began its journey in 1956 as New England Nuclear Corporation (NEN). While the specific identities of all its founders and their initial stakes are not widely documented, the company's inception was rooted in the field of diagnostic imaging. This early focus laid the groundwork for its future contributions to medical technology.

Founding Year

The company was established in 1956, marking the beginning of its operations in the diagnostic imaging sector.

Original Name

It was initially founded as New England Nuclear Corporation (NEN). This name reflected its early scientific and research-oriented beginnings.

Early Focus

The company's foundational activities were centered on diagnostic imaging. This specialization guided its development and strategic direction from the outset.

First Major Acquisition

In 1981, E.I. du Pont de Nemours and Company acquired NEN. This marked a significant shift in the company's ownership structure.

Subsequent Corporate Change

Later, Bristol-Myers Squibb Company (BMS) acquired the diagnostic medical imaging business. This occurred in 2001 as part of its larger acquisition of DuPont Pharmaceuticals.

Ownership Evolution

These early acquisitions illustrate how the company's ownership was influenced by major pharmaceutical and chemical entities. This reflects the strategic importance of its imaging capabilities.

The ownership history of the company, from its inception as New England Nuclear Corporation in 1956, has been characterized by significant corporate transitions. The acquisition by E.I. du Pont de Nemours and Company in 1981 represented a pivotal moment, moving ownership from its original founders to a larger conglomerate. This was followed by another major shift in 2001 when Bristol-Myers Squibb Company acquired the diagnostic medical imaging business, integrating it into its broader portfolio. These events highlight how the company's ownership has been shaped by strategic consolidations within the healthcare and pharmaceutical industries, underscoring the value placed on its diagnostic imaging technologies. Understanding these early stages is crucial for grasping the Revenue Streams & Business Model of Lantheus Medical Imaging as it evolved.

Key Ownership Milestones

The company's ownership structure underwent significant transformations in its early years, reflecting its growing importance in the medical imaging field.

• Founded in 1956 as New England Nuclear Corporation (NEN).
• Acquired by E.I. du Pont de Nemours and Company in 1981.
• Diagnostic medical imaging business acquired by Bristol-Myers Squibb Company in 2001.
• These acquisitions demonstrate the strategic interest from larger corporations in the company's imaging technologies.

Lantheus Medical Imaging SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership journey of Lantheus Holdings, Inc. saw a pivotal shift from corporate division to private equity, culminating in its public debut. This evolution significantly altered who owns Lantheus Medical Imaging.

Following its transition to a publicly traded entity in June 2015, Lantheus Holdings, Inc. now has a dispersed ownership structure primarily held by institutional investors. As of March 31, 2025, the company is owned by 1088 institutional entities holding over 101 million shares. This broad institutional backing signifies a significant level of professional investment and influences the company's strategic direction.

Key Institutional Shareholders

Major institutional investors hold substantial portions of Lantheus Holdings, Inc. stock, indicating their significant influence.

• BlackRock, Inc. holds 8,754,533 shares.
• Vanguard Group Inc. possesses 7,000,689 shares.
• Janus Henderson Group Plc owns 6,514,452 shares.
• Farallon Capital Management LLC has 6,023,227 shares.

Collectively, institutional investors and hedge funds command approximately 99.06% of the company's outstanding shares as of March 31, 2025. This concentration of ownership among professional investors underscores their role in shaping the company's governance and long-term strategy. Understanding these major stakeholders is crucial for comprehending the Lantheus Medical Imaging parent company's operational framework and its Marketing Strategy of Lantheus Medical Imaging.

Lantheus Medical Imaging PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The governance of Lantheus Holdings, Inc. is overseen by its Board of Directors, which includes key figures like Chairperson Mary Anne Heino and CEO Brian Markison. The board is composed of independent directors, ensuring diverse perspectives in strategic decision-making.

Lantheus employs a staggered board structure, meaning directors are elected for three-year terms, with one class up for election annually. While the company's 2025 proxy statement indicates a move towards a majority voting standard for uncontested director elections, it has historically operated under a plurality standard. This means a director could be elected with fewer than a majority of votes cast, a practice that has drawn attention from shareholders seeking greater accountability. The company does not have special voting rights or a poison pill defense mechanism in place, reflecting a standard corporate ownership structure for a public company.

Understanding Lantheus's Board and Voting Power

The composition and voting structure of Lantheus's Board of Directors are key to understanding its corporate ownership and decision-making processes. The shift towards majority voting for uncontested director elections is a significant governance development.

• Staggered board structure for director elections.
• Transition to majority voting standard for uncontested elections.
• Historical use of plurality voting standard.
• All directors are independent, except for the CEO and former CEO.
• No special voting rights or poison pill provisions.
• Understanding these elements is crucial for Lantheus Medical Imaging shareholders.

Lantheus Medical Imaging Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Lantheus Holdings, Inc. has seen significant shifts in its strategic direction and ownership landscape over the past few years. These changes reflect a proactive approach to portfolio enhancement and operational streamlining, impacting its overall corporate structure and stakeholder interests.

Institutional investors hold a dominant position in the company's ownership, accounting for 99.06% of the stock as of August 2025. While some large institutions have reduced their holdings, others have increased their stakes, indicating varied investor sentiment and strategic adjustments within the institutional landscape.

Strategic Acquisitions and Pipeline Expansion

Lantheus has actively expanded its pipeline through multiple acquisitions and in-licensing deals in 2024 and early 2025. Key additions include assets targeting prostate and Alzheimer's disease, alongside enhancements to its radioligand therapy capabilities.

Portfolio Streamlining and Focus Shift

The planned divestiture of the SPECT business signifies a strategic move to concentrate on PET radiodiagnostics and radiotherapeutic agents. This adjustment aims to sharpen the company's market focus and optimize resource allocation.

Leadership and Executive Transitions

Recent leadership changes, including a new CEO appointment and transitions in key medical and scientific roles, underscore the company's commitment to evolving its executive team. These changes are designed to support the company's strategic objectives and innovation efforts.

Shareholder Value and Capital Allocation

The authorization of a significant share repurchase program demonstrates management's confidence in the company's financial health and its dedication to enhancing shareholder returns. This initiative reflects a balanced approach to capital allocation, supporting growth while returning value to investors.

Lantheus Medical Imaging Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔